share_log

Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Maintains $12 Price Target

Benzinga ·  Jun 27, 2024 21:44

Canaccord Genuity analyst William Plovanic maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and maintains $12 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment